Updated March 28 at 10:39am

MultiCell Technologies updates research results

WOONSOCKET – MultiCell Technologies announced on Aug. 10 its updates on preclinical research results for MCT-465 and MCT-485, the first of a family of prospective cancer therapeutics based on the use of its patented signaling technology. MCT-465 and MCT-485 are being investigated as prospective treatments for primary liver cancer and triple-negative breast cancer. More

To continue reading this article, please do one of the following.



Sign up to receive Providence Business News' newsletters
and breaking news alerts.  

HEALTH CARE

MultiCell Technologies updates research results

Posted:

WOONSOCKET – MultiCell Technologies announced on Aug. 10 its updates on preclinical research results for MCT-465 and MCT-485, the first of a family of prospective cancer therapeutics based on the use of its patented signaling technology. MCT-465 and MCT-485 are being investigated as prospective treatments for primary liver cancer and triple-negative breast cancer.

The latest preclinical results for MCT-485 showed in vitro dose-effect cytotoxicity on several human hepatocellular carcinoma cell lines, according to the company. In contrast, MCT-465 showed no cytotoxicity or anti-proliferative effect, according to the company.

The research results support further mechanistic and in vivo studies exploring the safety, effectiveness and utility of MCT-465 and MCT-485 as novel therapeutic agents as a treatment for hepatocellular carcinoma and other cancers, according to MultiCell Technologies.

Hepatocellular carcinoma is the most common form of primary liver cancer and a leading cause of cancer death. Current pharmacological approaches for treatment have been very limited in their efficacy. •

27~20, 082012 HEALTH CARE NEWS BRIEFS, health services, biotechnology, life sciences, health care, MultiCell Technologies¸, 27~20, issue082012export.pbn

Comments

No comments on this story | Please log in to comment by clicking here
Please log in or register to add your comment
Latest News